142 related articles for article (PubMed ID: 16293676)
21. An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer.
Klein HO; Wils J; Bleiberg H; Buyse M; Duez N
Med Oncol Tumor Pharmacother; 1989; 6(2):171-4. PubMed ID: 2664372
[TBL] [Abstract][Full Text] [Related]
22. Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
Westermann AM; Taal BG; Swart M; Boot H; Craanen M; Gerritsen WR
Pharmacol Res; 2000 Aug; 42(2):151-6. PubMed ID: 10887044
[TBL] [Abstract][Full Text] [Related]
23. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
[TBL] [Abstract][Full Text] [Related]
24. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
Chua YJ; Cunningham D
Ann Surg Oncol; 2007 Oct; 14(10):2687-90. PubMed ID: 17653804
[No Abstract] [Full Text] [Related]
25. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
Jeung HC; Moon YW; Rha SY; Yoo NC; Roh JK; Noh SH; Min JS; Kim BS; Chung HC
Ann Oncol; 2008 Mar; 19(3):520-6. PubMed ID: 18029971
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI
Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
[TBL] [Abstract][Full Text] [Related]
28. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.
Coombes RC; Schein PS; Chilvers CE; Wils J; Beretta G; Bliss JM; Rutten A; Amadori D; Cortes-Funes H; Villar-Grimalt A
J Clin Oncol; 1990 Aug; 8(8):1362-9. PubMed ID: 2199622
[TBL] [Abstract][Full Text] [Related]
30. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
Briasoulis E; Fatouros M; Roukos DH
Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806
[No Abstract] [Full Text] [Related]
31. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer.
Tsavaris N; Tentas K; Kosmidis P; Mylonakis N; Sakelaropoulos N; Kosmas C; Lisaios B; Soumilas A; Mandrekas D; Tsetis A; Klonaris C
Chemotherapy; 1996; 42(3):220-6. PubMed ID: 8983891
[TBL] [Abstract][Full Text] [Related]
32. [Recent advances in chemotherapy for advanced gastric cancer: from the standpoint of survival advantages].
Ohtsu A; Yoshida S; Miyata Y; Shimada Y
Gan To Kagaku Ryoho; 1995 Mar; 22(4):444-50. PubMed ID: 7887636
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
Nashimoto A; Nakajima T; Furukawa H; Kitamura M; Kinoshita T; Yamamura Y; Sasako M; Kunii Y; Motohashi H; Yamamoto S;
J Clin Oncol; 2003 Jun; 21(12):2282-7. PubMed ID: 12805327
[TBL] [Abstract][Full Text] [Related]
34. The treatment of advanced gastric cancer.
Wils J
Semin Oncol; 1996 Jun; 23(3):397-406. PubMed ID: 8658224
[TBL] [Abstract][Full Text] [Related]
35. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
[TBL] [Abstract][Full Text] [Related]
36. Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction.
Bar Sela G; Tsalic M; Gaitini D; Steiner M; Haim N
J Chemother; 2002 Dec; 14(6):623-6. PubMed ID: 12583555
[TBL] [Abstract][Full Text] [Related]
37. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
[TBL] [Abstract][Full Text] [Related]
38. Phase-III clinical trial of adjuvant FAM2 (5-FU, adriamycin and mitomycin C) vs control in resectable gastric cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.
Lise M; Nitti D; Buyse M; Cartei G; Fornasiero A; Guimaraes dos Santos J; Duez N
Recent Results Cancer Res; 1988; 110():36-43. PubMed ID: 3043595
[No Abstract] [Full Text] [Related]
39. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
40. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up.
Neri B; Cini G; Andreoli F; Boffi B; Francesconi D; Mazzanti R; Medi F; Mercatelli A; Romano S; Siliani L; Tarquini R; Moretti R
Br J Cancer; 2001 Apr; 84(7):878-80. PubMed ID: 11286464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]